Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glyko launches FACE lysosomal disease screening test.

This article was originally published in The Gray Sheet

Executive Summary

GLYKO BIOMEDICAL BEGINS SALES OF FACE LYSOSOMAL DISEASE SCREEN following 510(k) clearance of the product on Nov. 3. The company says that the FACE (Fluorophore-Assisted Carbohydrate Electrophoresis) Urinary Carbohydrate Analysis Kit is the first FDA-cleared product for identification of "abnormal" carbohydrates associated with lysosomal diseases. The test can screen children for more than 25 lysosomal diseases, which stem from hereditary defects in the lysosomal enzymes that break down and recycle carbohydrates. The disorders, resulting from the accumulation in the body of incompletely degraded sugar chains, include Tay-Sachs, Gaucher's, Hurler and Hunter MPS diseases.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005052

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel